Science: Fibrobody®-Drug ConjugatesFibrobodies as first-in-class drug delivery vectors
Fibrobodies as first-in-class drug delivery vectors
Targeted drug delivery
Targeted drug delivery is successfully applied in the treatment of cancer, using conventional antibodies as the drug delivery vectors, in the form of Antibody-Drug Conjugates. For targeted drug delivery in fibrosis, these large and immune-activating molecules are not suitable.
Fibrobodies®, in contrast, were designed for this specific purpose.
FDCs
Fibrobody®-Drug ConjugatesThe core task of Fibrobodies® is to selectively deliver anti-fibrotic medicines to activated myofibroblasts, leaving the normal, healthy cells and tissues of the patient alone. This overcomes two barriers that have thus far hampered the development of antifibrotic medicines.
First, it can unlock the potential of medicines whose un-targeted use would be limited by side effects, by focusing their full force only onto the activated myofibroblasts.
Second, it can unlock the potential of medicines that would otherwise not reach the activated myofibroblasts at all – simply by getting them there.
